Comprehensive profiling of tumor samples taken from patients with osteosarcoma shows that multiple factors contribute to the traditionally poor responses observed from treatment with immune checkpoint inhibitors, according to new research.
from Health & Medicine News -- ScienceDaily https://www.sciencedaily.com/releases/2020/02/200221084811.htm
No comments:
Post a Comment